

Marina Picillo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1928542/marina-picillo-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

4,390
citations

38
h-index

60
g-index

171
ext. papers

5,412
ext. citations

4.3
avg, IF

5.24
L-index

#	Paper	IF	Citations
162	Uncovering clinical and radiological asymmetry in progressive supranuclear palsy-Richardson's syndrome.. <i>Neurological Sciences</i> , 2022 , 1	3.5	0
161	Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study.. <i>Parkinsonism and Related Disorders</i> , 2022 , 98, 72-74	3.6	
160	Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy. <i>Scientific Reports</i> , 2021 , 11, 21683	4.9	2
159	Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adults. <i>Neurological Sciences</i> , 2021 , 1	3.5	0
158	Energy expenditure, body composition and dietary habits in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2021 , 1	5.5	
157	Application of the mPSPRS to the Salerno Cohort and a Comparison Between PSP-RS and vPSP. <i>Movement Disorders</i> , 2021 , 36, 2449-2451	7	
156	Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians. <i>Aging and Mental Health</i> , 2021 , 25, 1998-2002	3.5	2
155	Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. <i>Parkinsonism and Related Disorders</i> , 2021 , 84, 82-90	3.6	1
154	Bipolar Disorder and Parkinson's Disease: A I-Ioflupane Dopamine Transporter SPECT Study. <i>Frontiers in Neurology</i> , 2021 , 12, 652375	4.1	0
153	Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease. <i>Scientific Reports</i> , 2021 , 11, 8936	4.9	3
152	Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages. <i>Scientific Reports</i> , 2021 , 11, 9297	4.9	5
151	Gait Analysis in Progressive Supranuclear Palsy Phenotypes. <i>Frontiers in Neurology</i> , 2021 , 12, 674495	4.1	0
150	The language profile in multiple system atrophy: an exploratory study. <i>Journal of Neural Transmission</i> , 2021 , 128, 1195-1203	4.3	0
149	Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 672-680	7	1
148	Impact of COVID-19 on neurological patients attending a botulinum toxin service. <i>Neurological Sciences</i> , 2021 , 42, 433-435	3.5	8
147	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021 , 268, 448-454	5.5	11
146	Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review. <i>Cells</i> , 2021 , 10,	7.9	3

145	Posterior Cortical Atrophy phenotype in a GBA N370S mutation carrier: a case report. <i>BMC Neurology</i> , 2021 , 21, 17	3.1	2
144	Cutaneous sensory and autonomic denervation in progressive supranuclear palsy. <i>Neuropathology and Applied Neurobiology</i> , 2021 , 47, 653-663	5.2	2
143	Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study. <i>Frontiers in Neurology</i> , 2021 , 12, 711358	4.1	0
142	Psychometric properties of the Beck Depression Inventory-II in progressive supranuclear palsy. <i>Brain and Behavior</i> , 2021 , 11, e2344	3.4	3
141	Efficacy of Safinamide and Gender Differences During Routine Clinical Practice.. <i>Frontiers in Neurology</i> , 2021 , 12, 756304	4.1	2
140	Prevalence of heterozygous mutations in Niemann-Pick type C genes in a cohort of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 9-10	3.6	3
139	Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes. <i>Journal of Alzheimers Disease</i> , 2020 , 76, 341-347	4.3	5
138	Managing Device-Aided Treatments in Parkinson's Disease in Times of COVID-19. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 737-738	2.2	1
137	Levodopa-carbidopa intestinal gel is an option in Parkinson's disease with hyponatremia induced by dopamine agonists. <i>Neurological Sciences</i> , 2020 , 41, 3361-3363	3.5	1
136	A Novel Phenotype Associated with -Related Familial Brain Calcifications. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 701-703	2.2	3
135	Effects of gender on cognitive and behavioral manifestations in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2020 , 127, 925-934	4.3	4
134	Childhood-onset dystonia with cerebellar signs: expanding the spectrum of GNAL mutations. <i>European Journal of Neurology</i> , 2020 , 27, e66-e67	6	
133	The role of disease duration and severity on novel clinical subtypes of Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 73, 31-34	3.6	6
132	Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020 , 72, 49-55	3.6	6
131	Corticobasal Degeneration Reveals Its Signature by Tau Strains. <i>Movement Disorders</i> , 2020 , 35, 934	7	
130	Theory of Mind in multiple system atrophy: comparison with Parkinson's disease and healthy subjects. <i>Journal of Neural Transmission</i> , 2020 , 127, 915-923	4.3	2
129	Deep brain stimulation of the ventralis oralis anterior thalamic nucleus is effective for dystonic tremor. <i>Parkinsonism and Related Disorders</i> , 2020 , 81, 8-11	3.6	3
128	Midbrain MRI assessments in progressive supranuclear palsy subtypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 98-103	5.5	19

127	Evolution of neuropsychological profile in motor subtypes of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020 , 70, 67-73	3.6	11
126	The "zig-zag" sign in Progressive Supranuclear Palsy. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 86-87	3.6	2
125	GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020 , 35, 2106-2111	7	35
124	Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2020 , 11, 603161	4.1	3
123	Machine learning can detect the presence of Mild cognitive impairment in patients affected by Parkinson's Disease 2020 ,		9
122	-Related Corticobasal Syndrome: Expanding the List of Corticobasal Degeneration Look Alikes. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 849-851	2.2	3
121	Dystonia as complication of thalamic neurosurgery. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 232-236	3.6	13
120	From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 272-273	3.6	6
119	Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy. <i>Neurological Sciences</i> , 2019 , 40, 2163-2169	3.5	3
118	Serotonergic pathology and disease burden in the premotor and motor phase of A53T α -synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , 2019 , 18, 748-759	24.1	44
117	Parkinson's disease management and impulse control disorders: current state and future perspectives. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 495-508	4.3	6
116	Motor, cognitive and behavioral differences in MDS PSP phenotypes. <i>Journal of Neurology</i> , 2019 , 266, 1727-1735	5.5	17
115	Comparing postural instability and gait disorder and akinetic-rigid subtyping of Parkinson disease and their stability over time. <i>European Journal of Neurology</i> , 2019 , 26, 1212-1218	6	10
114	The language profile of progressive supranuclear palsy. <i>Cortex</i> , 2019 , 115, 294-308	3.8	18
113	Validation of the Italian version of the PSP Quality of Life questionnaire. <i>Neurological Sciences</i> , 2019 , 40, 2587-2594	3.5	1
112	The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease. <i>European Journal of Neurology</i> , 2019 , 26, 1327-1333	6	13
111	Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy. <i>PLoS ONE</i> , 2019 , 14, e0223621	3.7	6
110	Serum miR-30c-5p is a potential biomarker for multiple system atrophy. <i>Molecular Biology Reports</i> , 2019 , 46, 1661-1666	2.8	10

109	Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations. <i>Cell Death and Disease</i> , 2018 , 9, 385	9.8	31
108	Medical Management of Movement Disorders. <i>Progress in Neurological Surgery</i> , 2018 , 33, 41-49	1.4	2
107	Predictors of deep brain stimulation outcome in tremor patients. <i>Brain Stimulation</i> , 2018 , 11, 592-599	5.1	31
106	When shaking during standing points to hereditary spastic paraplegias. <i>Parkinsonism and Related Disorders</i> , 2018 , 46, 92-94	3.6	3
105	MDS PSP criteria in real-life clinical setting: Motor and cognitive characterization of subtypes. <i>Movement Disorders</i> , 2018 , 33, 1361-1365	7	16
104	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. <i>Journal of Neurology</i> , 2018 , 265, 2211-2220	5.5	22
103	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. <i>Lancet Neurology</i> , 2018 , 17, 597-608	24.1	68
102	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study 2018 , 265, 2211		1
101	Apathy in Parkinson's disease: differences between caregiver's report and self-evaluation. <i>Functional Neurology</i> , 2018 , 33, 31-35	2.2	8
100	Parkinsonism due to A53E Bsynuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. <i>Movement Disorders</i> , 2018 , 33, 1950-1955	7	12
99	Interleaving Stimulation in Parkinson's Disease, Tremor, and Dystonia. <i>Stereotactic and Functional Neurosurgery</i> , 2018 , 96, 379-391	1.6	25
98	Screening for Aphasia in NeuroDegeneration for the Diagnosis of Patients with Primary Progressive Aphasia: Clinical Validity and Psychometric Properties. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018 , 46, 243-252	2.6	9
97	Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neurology</i> , 2018 , 265, 2602-2613	5.5	53
96	Deep Brain Stimulation Target Selection for Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 3-8	1	14
95	Progressive Supranuclear Palsy-Like Phenotype in a E326K Mutation Carrier. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 444-446	2.2	6
94	Early Ataxia and Subsequent Parkinsonism: PLA2G6 Mutations Cause a Continuum Rather Than Three Discrete Phenotypes. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 125-128	2.2	10
93	Two indications, one target: Concomitant epilepsy and Tourettism treated with Centromedian/parafascicular thalamic stimulation. <i>Brain Stimulation</i> , 2017 , 10, 711-713	5.1	4
92	Establishing a Standard of Care for Deep Brain Stimulation Centers in Canada. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 132-138	1	7

91	Exploring risk factors for stuttering development in Parkinson disease after deep brain stimulation. <i>Parkinsonism and Related Disorders</i> , 2017 , 38, 85-89	3.6	14
90	Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017 , 37, 106-110	3.6	23
89	Hepatitis C Virus-Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report. <i>Annals of Internal Medicine</i> , 2017 , 166, 379-380	8	4
88	The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. <i>European Journal of Neurology</i> , 2017 , 24, 788-795	6	29
87	The SAC1 domain in synaptojanin is required for autophagosome maturation at presynaptic terminals. <i>EMBO Journal</i> , 2017 , 36, 1392-1411	13	124
86	The relevance of gender in Parkinson's disease: a review. <i>Journal of Neurology</i> , 2017 , 264, 1583-1607	5.5	106
85	Quality of Life and Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 499-516	4.4	34
84	Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients. <i>Neurology</i> , 2017 , 89, 776-784	6.5	49
83	Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 652-662	2.2	3
82	Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation. <i>Neurogenetics</i> , 2017 , 18, 175-178	3	13
81	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0186508	3.7	21
80	The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. <i>European Journal of Neurology</i> , 2016 , 23, 1673-1679	6	55
79	Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation. <i>Canadian Journal of Neurological Sciences</i> , 2016 , 43, 626-34	1	18
78	Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study. <i>Journal of Neural Transmission</i> , 2016 , 123, 1399-1402	4.3	19
77	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. <i>Sleep</i> , 2016 , 39, 405-12	1.1	58
76	White matter changes and the development of motor phenotypes in de novo Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2016 , 367, 215-9	3.2	19
75	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 184-187	2.2	5
74	Programming Deep Brain Stimulation for Parkinson's Disease: The Toronto Western Hospital Algorithms. <i>Brain Stimulation</i> , 2016 , 9, 425-437	5.1	100

73	Programming Deep Brain Stimulation for Tremor and Dystonia: The Toronto Western Hospital Algorithms. <i>Brain Stimulation</i> , 2016 , 9, 438-452	5.1	50
72	Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016 , 123, 371-7	4.3	9
71	Recent advances in Essential Tremor: Surgical treatment. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S171-5	3.6	21
70	Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2016 , 1		2
69	Low-frequency Subthalamic Stimulation in Parkinson's Disease: Long-term Outcome and Predictors. <i>Brain Stimulation</i> , 2016 , 9, 774-779	5.1	33
68	Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2016 , 43, 462-71	1	40
67	Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 137-40	3.6	43
66	Gender and non motor fluctuations in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016 , 27, 89-92	3.6	29
65	Caffeine consumption and the 4-year progression of de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 32, 116-119	3.6	18
64	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 373-8	7	36
63	Recruitment strategies and patient selection in clinical trials for Parkinson's disease: Going viral and keeping science and ethics at the highest standards. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1041-8	3.6	20
62	Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy. <i>Journal of the Neurological Sciences</i> , 2015 , 350, 103-4	3.2	5
61	Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. <i>Journal of Neurology</i> , 2015 , 262, 425-34	5.5	126
60	Increased bilirubin levels in de novo Parkinson's disease. <i>European Journal of Neurology</i> , 2015 , 22, 954-9	6	19
59	Low-Frequency Stimulation of Globus Pallidus Internus for Axial Motor Symptoms of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 445-446	2.2	2
58	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1219-26	3.6	86
57	Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. <i>European Journal of Neurology</i> , 2015 , 22, 93-8	6	37
56	Uric acid relates to dopamine transporter availability in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015 , 131, 127-31	3.8	20

55	Non-Motor Correlates of Smoking Habits in de Novo Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2015 , 5, 913-24	5.3	4
54	Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study. <i>European Journal of Neurology</i> , 2015 , 22, 253-60	6	48
53	Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 413-416	2.2	
52	Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. <i>Acta Neurologica Scandinavica</i> , 2015 , 131, 275-81	3.8	31
51	Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 489-93	3.6	78
50	Subdural Continuous Theta Burst Stimulation of the Motor Cortex in Essential Tremor. <i>Brain Stimulation</i> , 2015 , 8, 840-2	5.1	19
49	Quitting smoking: an early non-motor feature of Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 216-20	3.6	15
48	Short-latency afferent inhibition in patients with Parkinson's disease and freezing of gait. <i>Journal of Neural Transmission</i> , 2015 , 122, 1533-40	4.3	20
47	The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. <i>Neurological Sciences</i> , 2014 , 35, 379-83	3.5	34
46	Clinical progression of SYNJ1-related early onset atypical parkinsonism: 3-year follow up of the original Italian family. <i>Journal of Neurology</i> , 2014 , 261, 823-4	5.5	10
45	Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014 , 27, 276-81	3.8	43
44	Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. <i>European Journal of Neurology</i> , 2014 , 21, 802-7	6	32
43	Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects. <i>Clinical Otolaryngology</i> , 2014 , 39, 53-7	1.8	7
42	Comment on Szeczyk-Krolkowski et al.: the influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1319-20	3.6	2
41	Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2014 , 261, 2112-8	5.5	28
40	PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family. <i>Neurogenetics</i> , 2014 , 15, 183-8	3	84
39	Gender differences in non-motor symptoms in early Parkinson's disease: a 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 850-4	3.6	43
38	How does smoking affect olfaction in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2014 , 340, 215-7	3.2	11

37	Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 772-5	3.6	21
36	Comment on Numao et al.: Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 680-1	3.6	
35	Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania. <i>Journal of Parkinsons Disease</i> , 2014 , 4, 123-8	5.3	6
34	Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. <i>Journal of Neurology</i> , 2014 , 261, 2319-28	5.5	61
33	Serpentine tongue in long-term metoclopramide treatment. <i>Neurology Psychiatry and Brain Research</i> , 2014 , 20, 93-95	2.1	2
32	Pallidal stimulation in atypical pantothenate kinase-associated neurodegeneration: six-year follow-up. <i>Movement Disorders</i> , 2014 , 29, 276-7	7	4
31	Evolution of mild cognitive impairment in Parkinson disease. <i>Neurology</i> , 2014 , 82, 1384	6.5	
30	Progressive parkinsonism, balance difficulties, and supranuclear gaze palsy. <i>JAMA Neurology</i> , 2014 , 71, 104-7	17.2	17
29	Subthreshold depression and subjective cognitive complaints in Parkinson's disease. <i>European Journal of Neurology</i> , 2014 , 21, 541-4	6	29
28	Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013 , 34, 683-7	3.5	85
27	Movement disorders as presenting symptoms of AIDS. <i>Basal Ganglia</i> , 2013 , 3, 175-178		1
26	Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. <i>Human Mutation</i> , 2013 , 34, 1208-15	4.7	208
25	Patients with Parkinson's disease and scans with (predominant) ipsilateral dopaminergic deficit. <i>Journal of Neurology</i> , 2013 , 260, 2405-6	5.5	8
24	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013 , 260, 1724-30	5.5	34
23	Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. <i>Journal of Neurology</i> , 2013 , 260, 714-40	5.5	52
22	Serum epidermal growth factor predicts cognitive functions in early, drug-naïve Parkinson's disease patients. <i>Journal of Neurology</i> , 2013 , 260, 438-44	5.5	39
21	Early MRI findings in acquired hepatocerebral degeneration. <i>Neurological Sciences</i> , 2013 , 34, 589-91	3.5	6
20	Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013 , 260, 2849-55	5.5	61

19	Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. <i>Movement Disorders</i> , 2013 , 28, 1391-7	7	86
18	Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 256-9	3.6	23
17	Segmental progression of cardinal motor symptoms in Parkinson's disease: a pilot study suggesting a practical approach to rate disease course in the early stages. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 1143-8	3.6	2
16	Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 14-7	5.5	77
15	Teaching NeuroImages: pseudo-abnormal DaTscan findings in meningioma-induced parkinsonism. <i>Neurology</i> , 2013 , 80, e147	6.5	2
14	The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. <i>PLoS ONE</i> , 2013 , 8, e70244	3.7	118
13	Hearing impairment in Parkinson's disease: expanding the nonmotor phenotype. <i>Movement Disorders</i> , 2012 , 27, 1530-5	7	67
12	Gait patterns in Parkinsonian patients with or without mild cognitive impairment. <i>Movement Disorders</i> , 2012 , 27, 1536-43	7	52
11	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naïve PD patients. <i>Journal of Neurology</i> , 2012 , 259, 1808-13	5.5	47
10	Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 781-7	3.6	177
9	Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 1034-8	3.6	72
8	Regional gray matter atrophy in patients with Parkinson disease and freezing of gait. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1804-9	4.4	89
7	Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. <i>Movement Disorders</i> , 2011 , 26, 1303-9	7	38
6	A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. <i>Movement Disorders</i> , 2010 , 25, 800-2	7	58
5	Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. <i>Brain</i> , 2009 , 132, 2350-5	11.2	92
4	Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2. <i>Movement Disorders</i> , 2009 , 24, 303-5	7	12
3	Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. <i>Movement Disorders</i> , 2009 , 24, 689-96	7	61
2	Dopamine receptor agonists and depression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 4, S81-4	3.6	18

1 Freezing of gait and executive functions in patients with Parkinson's disease. *Movement Disorders*, **2008**, 23, 395-400 7 223